STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
237: The 'electric vehicles' of pharma, Illumina's boondoggle, & a Theranos sentencing
STAT's Elaine Chen joins us to explain how the escalating demand for a potent diabetes drug is putting patients with obesity in a difficult situation. We also discuss a curious trend in biotech investing, the future of Illumina, and another sentencing in the Theranos saga.
236: Wither PhRMA, Alzheimer's treatment data revealed, and the first fecal microbiome drug approval
STAT Washington correspondent Rachel Cohrs joins us to explain how PhRMA, the all-powerful lobbying group, lost its edge in a fight over drug-pricing negotiation. Damian gives us the inside scoop on CTAD, the big Alzheimer's disease research conference, where Eisai and Biogen presented groundbreaking data on their treatment called lecanemab. We also discuss the FDA approval of a microbiome drug for the treatment of a bowel disorder and the potential for a big acquisition of Horizon Therapeutics.
235: LIVE from the STAT Summit
How do Alzheimer’s drugs even work? Can biotech people bake? And do we even like one another? Recorded live from the 2022 STAT Summit, we discuss the failure of an Alzheimer’s disease treatment from Roche, the unexpected success of a competing one for Eisai, and some unpredictable questions from our audience.
234: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy
STAT Washington correspondent Sarah Owermohle joins us to explain how this week's midterm elections will affect health and medicine, and what the politicization of the pandemic means for the future of science in the U.S. We also discuss the incoming CEOs of Biogen and Seagen, plus a pair of biotech collapses.
233: How the biotech revolution could come apart at the seams
Our colleague Matthew Herper joins us to discuss his thoughtful, personal story on how the biotech revolution that brought us genome editing, Covid-19 vaccines, and lifesaving medicines could run aground if humanity can't get out of its own way.
232: Anti-science at the polls, a biotech odd couple, & the stakes of the midterms
Our colleague Sarah Owermohle joins us to discuss how pandemic shutdowns, Covid-19 vaccines, and the prospect of arresting Anthony Fauci have become campaign rallying cries in midterm elections. We also discuss the latest news in the life sciences, including the potential effects of federal drug-price negotiation and the virtues of befriending Pharrell Williams.
Hi i love the podcast❤️❤️❤️❤️❤️❤️
Wrong Tone On the Murder for Hire
It sounds like someone was killed. If it was one of your close relatives you would be furious about the tone. Murder is serious, not funny, although I do understand that it’s not usually your beat. You come off as young, naive and lacking in character and wisdom.
Great for people who follow the biotech industry
Does a great job of reporting on and discussing the important developments in the biotech industry.